TLSI — TriSalus Life Sciences Share News
0.000.00%
Last trade - 00:00- $225.36m
- $212.14m
- $45.15m
Brief: Trisalus Life Sciences Receives FDA Clearance For Trinav Advance
TriSalus Life Sciences Inc reports results for the quarter ended June 30 - Earnings Summary
TriSalus Life Sciences Q2 revenue beats estimates
TriSalus Life Sciences Inc expected to post a loss of 15 cents a share - Earnings Preview
NASDAQ RESUMED AT 09:47 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:31 AM
TriSalus Life Sciences Q1 revenue falls 2.9%, misses estimates
TriSalus beats Q4 revenue estimates, reaffirms 2026 guidance
Brief: Trisalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky To Its Board Of Directors
Brief: Trisalus Life Sciences Launches Trinav® Xp Infusion System To Expand Options For Pressure-Enabled Drug Delivery™
Brief: TriSalus Life Sciences Files For Mixed Shelf Of Up To $150 Million - SEC Filing
Cancer therapy firm TriSalus Q3 revenue misses estimates
TriSalus Life Sciences Inc reports results for the quarter ended June 30 - Earnings Summary
TriSalus Life Sciences Inc expected to post a loss of 22 cents a share - Earnings Preview
Brief: TriSalus Life Sciences Announces Commencement Of Exchange Offer, Consent Solicitation Relating To Series A Convertible Preferred Stock To Streamline Capital Structure
TriSalus Life Sciences Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Trisalus Life Sciences Q1 Pretax Profit USD -10.37 Million
TriSalus Life Sciences Inc expected to post a loss of 22 cents a share - Earnings Preview
Brief: Trisalus Life Sciences Announces $22.0 Mln Private Placement